Pfizer Taps Kyowa Hakko Kirin For New Cancer Combo Study
This article was originally published in PharmAsia News
Pfizer has chosen Japan's Kyowa Hakko Kirin (KHK) as its latest partner to investigate an immunotherapy approach to cancer through a joint study for a combination of their respective novel monoclonal antibodies.
You may also be interested in...
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.